Thirteen pharmacies nationwide had at least a thousand courses of COVID-19 therapeutics available for clinical care at the start of this week, according to HHS data.
Therapeutics include Merck's antiviral molnupiravir, Pfizer's antiviral Paxlovid and AstraZeneca's monoclonal antibody treatment Evusheld. Medication volumes represent data as of Jan. 17 or Jan. 18, the most recent data available.
Note: The list includes ties and results in a numerical listing of 11.
- Alto Pharmacy (New York City) — 5,223 courses of molnupiravir available as of Jan. 18
- Publix Pharmacy (Fort Lauderdale, Fla.) — 3,060 courses of molnupiravir available as of Jan. 17
Publix Pharmacy (West Palm Beach, Fla.) — 3,060 courses of molnupiravir available as of Jan. 17 - Publix Pharmacy (Miami) — 3,059 courses of molnupiravir available as of Jan. 17
Publix Pharmacy (Punta Gorda, Fla.) — 3,059 courses of molnupiravir available as of Jan. 17 - Publix Pharmacy (Sebring, Fla.) 3,040 courses of molnupiravir available as of Jan. 17
- Mercy Hospital St. Louis — 2,213 courses of molnupiravir available as of Jan. 17
- Alto Pharmacy (New York City) — 1,630 courses of Paxlovid available as of Jan. 18
- Cleveland Clinic (main campus) — 1,595 courses of molnupiravir available as of Jan. 17
- Walgreens (Rock Hill, S.C.) — 1,191 courses of molnupiravir available as of Jan. 18
- Walgreens (Hartsville, S.C.) — 1,142 courses of molnupiravir available as of Jan. 18
- Walgreens (Elizabethtown, Ky.) — 1,070 courses of molnupiravir available as of Jan. 18
- AdventHealth Apopka (Fla.) — 1,056 courses of Evusheld available as of Jan. 18
Editor's note: This article was updated Jan. 19 at 3:05 p.m. CT. A previous version of this article included an incorrect therapeutics volume for Inova Pharmacy Plus in Fairfax, Va. Becker's regrets this error.